Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Other Non-Current Liabilities data on file, last reported at $379000.0 in Q3 2023.

• On a quarterly basis, Other Non-Current Liabilities changed 0.0% year-over-year to $379000.0 in Q3 2023; TTM through Sep 2023 was $379000.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $379000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities for Q3 2023 stood at $379000.0, roughly flat from $379000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for DNLI reached as high as $701000.0 in Q4 2020 and fell as low as $379000.0 in Q4 2019.
• Historically, Other Non-Current Liabilities has averaged $451894.7 across 5 years, with a median of $379000.0 in 2019.
• Across the five-year window, Other Non-Current Liabilities surged 211.29% in 2019 and slumped 45.93% in 2021, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $379000.0 in 2019, then jumped by 84.96% to $701000.0 in 2020, then slumped by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $379000.0 in Q3 2023, $379000.0 in Q2 2023, and $379000.0 in Q1 2023.